The USFDA has issued 8 observations for the drug product facility and API facility at Mandideep. The US drug regulator has inspected company’s Mandideep unit-1 facility during November 14-23, 2022.
Pankaj Tibrewal sees stronger top-line growth driving India’s next earnings cycle
Indian companies are poised to navigate input cost pressures and sustain growth, with the upcoming earnings season expected to be the next market trigger. Experts